Atypical antipsychotic effects of quetiapine fumarate in animal models

Acta Pharmacologica Sinica

Volumn 21, Issue 3, 2000, Pages 205-210

  Guan, Han Jun ^a   Dai, Jin ^a   Zhu, Xing Zu ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Antipsychotic agents; Basal ganglia diseases; Clozapine; Depression; Haloperidol; Phencyclidine; Quetiapine fumarate; Schizophrenia and disorders with psychotic features; Swimming

Indexed keywords

AMPHETAMINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; PHENCYCLIDINE; QUETIAPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FORCED SWIMMING TEST; MALE; MOUSE; NEGATIVE SYNDROME; NONHUMAN; PSYCHOSIS; SCHIZOPHRENIA;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CLOZAPINE; DISEASE MODELS, ANIMAL; FEMALE; HALOPERIDOL; IMMOBILIZATION; MALE; MICE; PHENCYCLIDINE; RATS; RATS, WISTAR; SCHIZOPHRENIA; SCHIZOPHRENIA, PARANOID;

EID: 0034026520     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Noda Y, Yamada K, Furukawa H, Nabeshima T. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br J Pharmacol 1995; 116: 2531-7.
2. Wetzel H, Szefedi A, Hain CH, Wiesner J, Schlegel S, Benkert O. ICI 204 636 (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: Results of an open clinical trial and changes of neuroendocrinological and EEG parameters. Psychopharmacology 1995; 119; 231-8.
3. Arvanitis L, Millerr BG, Link CGC. Seroquel (ICI 204 636): a novel atypical antipsychotic: efficacy and safety results from two phase II, multicenter, placebo controlled clinical trials. Schizophr Res 1995; 15: 142.
4. Migler BM, Warawa EJ, Malick JB. Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology 1993; 112: 299-307.
5. Ellenbroek BA, Peeters BW, Honig WM, Cools AR. The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology 1987; 93: 343-8.
6. Ellenbroek BA, Lubbers LJ, Cools AR. Activity of "seroquel" (ICI 204 636) in animal models for atypical properties of antipsychotics: a comparison with clozapine. Neuropsychopharmacology 1996; 15: 406-16.
7. Nabeshima T, Noda Y, Furukawa H, Kameyama T. Phencyclidine decrease binding capacity of serotonin 2 receptor in vitro . Res Commun Subst Abuse 1984; 5: 175-86.
8. Kitaichi K, Yamada K, Hasegawa T, Furukawa H, Nabeshima T. Effects of risperidone on phencyclidine-induced behaviors: Comparison with haloperidol and ritanserin. Jpn J Pharmacol 1994; 66: 181-9.
9. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993; 112: 285-92.
10. Sayed Y, Garrison JM. The dopamine hypothesis of schizophrenia and the antagonistic action of neuroleptic drugs - a review. Psychopharmacol Bull 1983; 19: 283-8.
11. Fabre LF, Arvanitis LA, Pultz L, Jones VM, Malick JB, Slotnick VB. Seroquel™ (ICI 204 636), a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 1995; 17; 366-78.
12. 2 antagonism and EPS benefits: is there a causal connection? Psychopharmacology 1996; 124: 35-9.
13. Ellenbroek BA, Prinssen EPM, Cools AR. The role of serotonin receptor subtypes in the behavioral effects of neuroleptic drugs: a paw test study in rats. Eur J Neurosci 1994, 6: 1-8.